[Correspondence] Unanswered questions from the NIMBLE trial
Source 柳叶刀 Lancet9d ago
Summary
Tuan Vu and colleagues reported that cemdisiran monotherapy (76·6% mean reduction from baseline in total complement haemolysis activity [CH50] inhibition) and…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- United Kingdom
- Language
- English
- Item ID
- health-c991f144
Comments 0 comments
No comments yet. Be the first.